The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis

Bibliography

• MacGregor AJ, Silman AJ. Classification and epidemiology. In: Hochberg MC, Silman AJ, Smolen JS, , Rheumatology. 3rd edition. Elsevier Science, Philadelphia, PA, USA; 2003. p. 757-763
   Google Scholar
• Dunlop DD, Manheim LM, Yelin EH, The costs of arthritis. Arthritis Rheum 2003;49:101-13
   PubMed Web of Science ®Google Scholar
• Lacaille D. Arthritis and employment research: where are we? Where do we need to go? J Rheumatol 2005;72:42-5
   Google Scholar
• Kavanaugh A. Economic issues with new rheumatologic therapeutics. Curr Opin Rheumatol 2007;19:272-6
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008;8:S49-60
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004;31:849-55
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Helmick CG, Arnett FC, Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99
   PubMed Web of Science ®Google Scholar
• Kirwan JR, Hewlett S. Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis. J Rheumatol 2007;34:1171-3
   PubMed Web of Science ®Google Scholar
• Albers JM, Kuper HH, Van Riel PL, Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology 1999;38:423-30
   PubMed Web of Science ®Google Scholar
• Young A, Dixey J, Cox N, How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology 2000;39:603-11
   PubMed Web of Science ®Google Scholar
• Young A, Dixey J, Kulinskaya E, Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002;61:335-40
   PubMed Web of Science ®Google Scholar
• Kavanaugh A. Health economics: implications for novel antirheumatic therapies. Ann Rheum Dis 2005;64:iv65-9
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol 2005;32:1875-83
   PubMed Web of Science ®Google Scholar
• Aletaha D, Eberl G, Nell VP, Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 2004;63:1269-75
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93
   PubMed Web of Science ®Google Scholar
• Breedveld FC. Should rheumatoid arthritis be treated conservatively or aggressively? Rheumatology 2003;42(Suppl 2):ii41-3
   PubMedGoogle Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-7
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW, Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Fleischmann RM, Long-term safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005;32:1232-42
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. Lancet 2004;364:263-9
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde DM, de Jager JP, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675-81
   PubMed Web of Science ®Google Scholar
• Lard LR, Visser H, Speyer I, Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51
   PubMed Web of Science ®Google Scholar
• Proudman SM, Conaghan PG, Richardson C, Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000;43:1809-19
   PubMed Web of Science ®Google Scholar
• Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003;21:S209-10
   PubMed Web of Science ®Google Scholar
• Smolen JS. Objectives and strategies for rheumatoid arthritis therapy: yesterday vs today. Drugs Today 2003;39(Suppl B):3-8
   PubMed Web of Science ®Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 2008;372:375-82
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23
   PubMed Web of Science ®Google Scholar
• Schiff MH, Pritchard C, Huffstutter JE, The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009;68:1708-14
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomized placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003, 62:1195-8
   PubMed Web of Science ®Google Scholar
• Hyrich K, Lunt M, Watson K, ; for the British Society for Rheumatology Biologics Registry. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20
   PubMed Web of Science ®Google Scholar
• Chapman A, Antonio P, Spitali M, Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999;17:780-3
   PubMed Web of Science ®Google Scholar
• Bourne T, Fossati G, Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn's disease: exploring a new mechanism of action. BioDrugs 2008;22:331-7
   PubMed Web of Science ®Google Scholar
• Certolizumab Pegol Product Information. UCB, Smyrna GA; 2009
   Google Scholar
• Nesbitt A, Fossati G, Bergin M, Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Brown D, Effects of structure of conventional anti-TNFs and certolizumab pegol on mode of action in rheumatoid arthritis. Ann Rheum Dis 2007;66:296-8
   Web of Science ®Google Scholar
• Lacroix B, Lovern M, Stockis A, Exposure-response modeling and simulations of the ACR20 response with different dosing regimens of certolizumab pegol in rheumatoid arthritis patients. Ann Rheum Dis 2008;67(Suppl 11): abstract FRI0110
   Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven R, Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
   PubMed Web of Science ®Google Scholar
• Van Riel PL, van Gestel AM, van de Putte LB, Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol 1996;35(Suppl 2):4-7
   PubMedGoogle Scholar
• Kirwan J, Reeback J. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9
   PubMedGoogle Scholar
• Hewlett S, Hehir M, Kirwan J. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum 2007;57:429-39
   PubMed Web of Science ®Google Scholar
• Ware J, Snow K, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. New England Medical Center/The Health Institute. Boston, MA; 1993
   Google Scholar
• Ware J, Kosinski M, Keller SK. SF-36 physical and mental health summary scales: a user's guide. New England Medical Center/The Health Institute. Boston, MA; 1994
   Google Scholar
• Wells G, Tugwell P, Kraag J, Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60
   PubMed Web of Science ®Google Scholar
• Dworkin R, Turk D, Wyrwich K, Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21
   PubMed Web of Science ®Google Scholar
• Wells G, Li T, Maxwell L, Determining the minimal clinically important differences in activity, fatigue and sleep quality in patients with rheumatoid arthritis. J Rheumatol 2007;34:280-9
   PubMed Web of Science ®Google Scholar
• Keystone E, van der Heijde D, Mason D Jr, Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, Van Riel PL, Nuver-Zwart IH, Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8
   PubMed Web of Science ®Google Scholar
• Strand V, Mease P, Burmester G.R, Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther 2009;11:R170
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe RB, Mease PJ, Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 Study. Ann Rheum Dis 2009;68:797-804
   Google Scholar
• Keystone E, Fleischmann R, Smolen JS, The efficacy of certolizumab pegol added to methotrexate is sustained over 2 years in the treatment of rheumatoid arthritis. Arthritis Rheum 2009;60(Suppl 9): abstract 1666
   PubMed Web of Science ®Google Scholar
• Strand V, Fleischmann R, Kvien T, Certolizumab pegol (CZP) added to methotrexate (MTX) provides lasting improvements in patient-reported outcomes (PROs) Over 2 Years. Arthritis Rheum 2009;60(Suppl 9): abstract 1698
   Google Scholar
• Mease P, Coteur G, Keininger DL, Improvements in physical function and pain relief were sustained in rheumatoid arthritis patients treated for 2 years with certolizumab pegol. Arthritis Rheum 2008;58(Suppl 9): abstract 980
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40
   PubMed Web of Science ®Google Scholar
• Habib G, Artul S, Ratson N, Froom P. Household work disability of Arab housewives with rheumatoid arthritis. Clin Rheumatol 2007;26:759-63
   PubMed Web of Science ®Google Scholar
• Soderlin MK, Kautiainen H, Skogh T, Leirisalo-Repo M. Quality of life and economic burden of illness in very early arthritis. A population based study in southern Sweden. J Rheumatol 2004;31:1717-22
   PubMed Web of Science ®Google Scholar
• van Jaarsveld CH, Jacobs JW, Schrijvers AJ, Effects of rheumatoid arthritis on employment and social participation during the first years of disease in The Netherlands. Br.J Rheumatol 1998;37:848-53
   PubMedGoogle Scholar
• Westhoff G, Listing J, Zink A. Loss of physical independence in rheumatoid arthritis: interview data from a representative sample of patients in rheumatologic care. Arthritis Care Res 2000;13:11-22
   PubMed Web of Science ®Google Scholar
• Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 2009;26:1681-5
   Google Scholar
• Escorpizo R, Bombardier C, Boonen A, Worker productivity outcome measures in arthritis. J Rheumatol 2007;34:1372-80
   PubMed Web of Science ®Google Scholar
• Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care 2006;44:304-10
   PubMed Web of Science ®Google Scholar
• Osterhaus JT, Purcaru O, Richard L. Discriminate validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res Ther 2009;11:R73-76
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Smolen JS, Emery P, Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum 2009;61:1592-600
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Smolen JS, Schiff M, Safety update on certolizumab pegol (CZP) in patients with active rheumatoid arthritis (RA). Arthritis Rheum 2009;60(Suppl 9): abstract 1699
   PubMed Web of Science ®Google Scholar